Patents by Inventor Ginger C. Rakestraw
Ginger C. Rakestraw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11858979Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: February 16, 2021Date of Patent: January 2, 2024Assignee: Bristol-Meyers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20230312686Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: November 10, 2022Publication date: October 5, 2023Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C, RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, JR., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, III, Christina TERRAGNI
-
Patent number: 11524992Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: GrantFiled: January 24, 2020Date of Patent: December 13, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
-
Publication number: 20220332817Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: ApplicationFiled: July 15, 2020Publication date: October 20, 2022Inventors: Achal M. PASHINE, Joseph TOTH, Ginger C. RAKESTRAW
-
Publication number: 20220204618Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: ApplicationFiled: February 11, 2022Publication date: June 30, 2022Inventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Patent number: 11274150Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: GrantFiled: November 14, 2019Date of Patent: March 15, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Publication number: 20210395392Abstract: This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.Type: ApplicationFiled: October 8, 2019Publication date: December 23, 2021Inventors: Thomas E. Spires, Jr., Michael Quigley, Virginie Lafont, Ginger C. Rakestraw, Linda Liang, Karen A. Augustine-Rauch
-
Publication number: 20210277089Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: February 16, 2021Publication date: September 9, 2021Inventors: Ray CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
-
Patent number: 10947297Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: November 21, 2017Date of Patent: March 16, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20200262893Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: January 24, 2020Publication date: August 20, 2020Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C. RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, Jr., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, Christina TERRAGNI
-
Publication number: 20200199226Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: ApplicationFiled: November 14, 2019Publication date: June 25, 2020Inventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Patent number: 10584160Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: GrantFiled: September 22, 2016Date of Patent: March 10, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
-
Publication number: 20190077844Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: September 22, 2016Publication date: March 14, 2019Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C. RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, JR., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, Christina TERRAGNI
-
Publication number: 20180201665Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: November 21, 2017Publication date: July 19, 2018Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Patent number: 9856309Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: December 2, 2015Date of Patent: January 2, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20170326249Abstract: An antibody-drug conjugate having a structure represented by formula (I) wherein m is 1, 2, 3, or 4 and Ab is an anti-glypican-3 antibody having heavy and light chain CDRs as disclosed herein.Type: ApplicationFiled: May 5, 2017Publication date: November 16, 2017Inventors: Chin PAN, Josephine M. CARDARELLI, Haichun HUANG, Sanjeev GANGWAR, Qiang CONG, Karla A. HENNING, Chetana RAO-NAIK, Mohan SRINIVASAN, Vangipuram S. RANGAN, Francis Y. LEE, Ginger C. RAKESTRAW
-
Publication number: 20160159883Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: December 2, 2015Publication date: June 9, 2016Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Patent number: 9234027Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: March 15, 2013Date of Patent: January 12, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Patent number: 8420098Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: GrantFiled: April 13, 2011Date of Patent: April 16, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20120094909Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: April 13, 2011Publication date: April 19, 2012Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff